BRAF and melanoma: The patients included in the analysis were divided into three study cohorts: (a) those with advanced melanoma with BRAFV600 mutations that had relapsed after treatment with BRAF, MEK, or BRAF/MEK combination therapy; (b) advanced melanoma harboring a NRASQ61X mutation; and (c) advanced NSCLC or colorectal carcinoma with a KRAS or BRAF mutation.